drugset / Trial / NCT03557970
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2
Terminated
3 enrolled
OHSU Knight Cancer Institute
Janssen, LP · collabOregon Health and Science University · collabThe Leukemia and Lymphoma Society · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well edicotinib (JNJ-40346527) works in treating participants with acute myeloid leukemia that has come back or does not respond to treatment. JNJ-40346527 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2018-10-05
- Primary completion
- 2020-09-28
- Completion
- 2020-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-40346527 | Unknown | — | Oral |